バイオテクノロジー・ライフサイエンスに特化したベンチャーキャピタル

MBLベンチャーキャピタル株式会社

About

Founded as a subsidiary of MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (MBL), one of the leading biotechnology companies in Japan.

Wide and plenty of investment and business experiences covers from start-up to IPO

Broad and strong network in the Industry, Academia and the Research Institutes worldwide.

But mblVC is “not” a corporate venture capital arm of MBL.

MBL business field does not narrow our investment target area.

Focuses only Lifescience related investments.

Utilize our considerable experience and expertise in lifescience industry.

We provide our portfolio companies not only money but:

business resources in Japan and other countries, utilizing MBL Group and other network including JSR

Profile

MBL Venture Capital Co., Ltd.

Establishment

January 12, 2000

Office

2nd Floor Ogawa Bldg., 1-2-2 Uchikanda, Chiyoda-ku, Tokyo 101-0047 JAPAN

Shareholder

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. 100% Link

Team

President / Yasuyo KAYAMA

Senior Manager / Masako HASHIMOTO

Manager / Masaya ISHIBASI

Board Member / Takashi MORITSU

Board Member /Kimimasa YAMADA

Venture Capitalist

  • Masako HASHIMOTO

    Ms. Masako Hashimoto joined mblVC in March 2014. Prior to joining mblVC, she served as General Manager at Yasuda Enterprise Development Co., Ltd., Japan's major VC firm with $800M under management, from 2007 to 2014. She headed Yasuda’s Life Science investment team both in the US and in Japan and her team invested more than $50M. Prior to Yasuda, she was a venture capitalist since 1990 to 1999, with Nippon Enterprise Development Co., Ltd., one of the oldest venture capital firm in Japan. She graduated Tokyo University of Foreign Studies.

JMLF

Recently we launched the new fund:
JSR・mblVC LifeScience Investment Limited Partnership(JMLF)

Fund Size

JPY3,000M (US$30M)

Fund Period

12years (~2026/3/24)

Allocation “Plan”

US: 60% JAPAN:40%

Features

Co-GP with JSR Life Science Venture Capital LLC Link
Easy Access to MBL and to JSR

Investment Field

We invest in the emerging companies in the following areas:

Therapeutics

Drug Discovery

Therapeutic Instruments

Diagnostics

Molecular Diagnostics

Diagnostic Services

Diagnostic Devices (ex. Microfluidics, POCT)

Others

Drug Delivery System

Investment Strategy

Investment Stage

Start-up ~ pre-IPO

Investment Size

US$1M ~ US$2M for initial investment

US$2M ~ US$3M per company

Region

Principally in North America and in Japan

Secondarily in European countries

Syndicate

Prefer to be a part of an investment syndicate with leading VC firms

Board Observation Right

Preferable but not a necessary condition

Access

PAGE TOP